XML 44 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Organization and Basis of Presentation - Other - (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Nov. 21, 2019
Jul. 22, 2019
Jun. 27, 2019
Jun. 19, 2019
Sep. 30, 2019
Jun. 30, 2019
Dec. 31, 2019
Dec. 31, 2017
Organization and basis of presentation information                
Payment of debt assumed in the Avedro Merger             $ 22,496  
In-process research and development expensed         $ 1,500 $ 2,245 $ 3,745 $ 5,320
Licensing Arrangement with Intratus, Inc.                
Organization and basis of presentation information                
In-process research and development expensed   $ 1,500            
Cash payments for the acquisition of certain assets   $ 1,500            
Avedro                
Organization and basis of presentation information                
Number of shares received in connection with Merger for each share of company owned stock 0.365              
Exchange Ratio (as a percent) 36.50%              
Total Merger Consideration $ 437,751              
Fair value of Glaukos common stock issued in the Merger, plus an immaterial amount of cash paid for fractional shares 406,776              
Fair value of Replacement Awards attributable to pre-combination services 30,786              
Fair value of Glaukos common stock issued to replace certain vested Avedro warrants 189              
Payment of debt assumed in the Avedro Merger (22,500)              
Capitalized property and equipment $ 1,489              
DOSE Medical Corporation                
Organization and basis of presentation information                
Period for U.S. Food and Drug Administration (FDA) approval for additional consideration       10 years        
Period for EU European Medicines Agency approval for additional consideration       10 years        
Quarterly royalty rate (as a percent)       5.00%        
Period for the quarterly royalty rate payments       10 years        
Cash payments for the acquisition of certain assets of related party     $ 2,500 $ 2,500        
In-process research and development expense     2,200          
Capitalized property and equipment     $ 300          
DOSE Medical Corporation | Minimum                
Organization and basis of presentation information                
Additional future consideration for U.S. Food and Drug Administration (FDA) approval       5,000        
Additional future consideration for European Medicines Agency approval       1,250        
Additional future consideration for certain net sales milestones       7,500        
Buyout of additional consideration amount       10,000        
DOSE Medical Corporation | Maximum                
Organization and basis of presentation information                
Additional future consideration for U.S. Food and Drug Administration (FDA) approval       22,500        
Additional future consideration for European Medicines Agency approval       2,500        
Additional future consideration for certain net sales milestones       20,000        
Buyout of additional consideration amount       $ 55,000